Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833996 | 0.97 | TSHR (0.52) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL5174514 | 0.97 | TSHR (0.52) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL16140792 | 0.97 | TSHR (0.52) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL17022252 | 0.97 | TSHR (0.52) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL16527588 | 0.91 | TSHR (0.46) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL267542 | 0.86 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4149480 | 0.86 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4140372 | 0.86 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4154180 | 0.86 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4143916 | 0.86 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327093-A | Synthesis method of Biolimus A9 | 福建省微生物研究所 | 2024-01-02 | — | — | CN | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021188620-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2513028-B1 | METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, USE OF SAID ALIZARIN COMPOUND, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR | FUJIFILM CORP (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-8741513-B2 | Method for preparing alizarin derivative compound, novel alizarin derivative compound, surface modification method, photoelectric conversion film, photoelectric conversion element, and electrophotographic photoreceptor | FUJIFILM CORPORATION (JP) | 2014-06-03 | — | — | US | disclosed |
| US-8633223-B2 | Process for preparation of 2-methyl-2′-phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2014-01-21 | — | — | US | disclosed |
| US-8487106-B2 | Process for preparation of 2-methyl-2′-phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2013-07-16 | — | — | US | disclosed |
| US-20130116466-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2013-05-09 | — | — | US | disclosed |
| US-5064863-A | Catabolic activity, obesity, diabetes | HOFFMANN-LA ROCHE INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-5028617-A | Heteroarylethanol-pyridylalkylamines for controlling animal growth | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-02 | — | — | US | disclosed |
| US-5017619-A | Anitdiabetic | HOFFMANN-LA ROCHE INC. (US) | 1991-05-21 | — | — | US | disclosed |
| US-4988714-A | Drugs for treatment of obesity and diabetics, increases protein breakdown, for fattening animals | HOFFMANN-LA ROCHE INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0379928-A2 | Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| EP-0375076-A1 | Heterocyclic herbicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-06-27 | — | — | EP | disclosed |
| CN-1042356-A | 1, 4-diaza * derivatives and their pharmaceutical use | EISAI CO LTD (JP) | 1990-05-23 | — | — | CN | disclosed |
| CN-1005711-B | Preparation method of phenoxypropanolamine compounds | 弗·哈夫曼-拉罗彻公司 | 1989-11-08 | — | — | CN | disclosed |
| US-4800206-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-01-24 | — | — | US | disclosed |
| CN-85101280-A | Benzene oxygen propanol amine compounds | — | 1987-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | TSHR 4157/4885ALDH1A1 3437/4885USP2 1389/4885 |
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH2, HRH4, HNMT | TSHR 3829/4885ALDH1A1 277/4885USP2 581/4885 |
| US-20130116466-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH1, HRH2, HRH4 | TSHR 3821/4885ALDH1A1 192/4885USP2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.